Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting

Journal of Korean Medical Science

Volumn 25, Issue 3, 2010, Pages 337-341

  Choi, Kyung Hee ^a   Kim, Ah Jeong ^a   Son, In Ja ^a   Kim, Kyung Hwan ^b   Kim, Ki Bong ^b   Ahn, Hyuk ^b   Lee, Eun Bong ^b,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Anti Inflammatory agents; Drug interactions; Non Steroidal; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; DRUG INTERACTIONS; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; THIAZINES; THIAZOLES; WARFARIN;

EID: 77952309339     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.3.337     Document Type: Article

References (25)

1. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367: 404-11.
2. Blann AD, Fitzmaurice DA, Lip GY. Anticoagulation in hospitals and general practice. BMJ 2003; 326: 153-6.
3. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk of primary intracerebral haemorhage associated with aspirin and nonsteroidal anti-inflammatory drugs: case-control study. BMJ 1999; 318: 759-64.
4. van Dijk KN, Plat AW, van Dijk AA, Piersma-Wichers M, de Vries-Bots AM, Slomp J, de Jong-van den Berg LT, Brouwers JR. Potential interaction between acenocoumarol and diclofenac naproxen and ibuprofen and role of CYP2C9 genotype. Thromb Haemost 2004; 91: 95-101.
5. Brouwers JR, De Smet PA. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1994; 27: 462-85.
6. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996; 30: 416-44.
7. Knijff-Dutmer EAH, Schut GA, van de Laar MA. Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacother 2003; 37: 12-6.
8. Chan TY. Prolongation of prothrombin time with the use of indomethacin and warfarin. Br J Clin Pract 1997; 51: 177-8.
9. Haasse KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential interaction between celecoxib and warfarin. Ann Pharmacother 2000; 34: 666-7.
10. Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother 2000; 34: 325-7.
11. Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm 2001; 58: 2076-80.
12. Schaefer MG, Plowman BK, Morreale AP, Egan M. Interaction of rofecoxib and celecoxib with warfarin. Am J Health Syst Pharm 2003; 60: 1319-23.
13. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-83.
14. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153: 1557-62.
15. Baxter K. Anticoagulants. In: Baxter K ed. Stockely's drug interactions. 7th ed. London: Pharmaceutical Press 2006: 255-327.
16. Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, Lens S, Porras AG, Dieck J, Keymeulen B, Gertz BJ. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. Clin Pharmacol Ther 2000; 68: 626-36.
17. Turck D, Su CA, Heinzel G, Busch U, Bluhmki E, Hoffmann J. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 1997; 51: 421-5.
18. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-15.
19. Schauer DP, Johnston JA, Moomaw CJ, Wess M, Eckman MH. Racial disparities in the filling of warfarin prescriptions for nonvalvular atrial fibrillation. Am J Med Sci 2007; 333: 67-73.
20. Hekselman I, Kahan NR, Ellis M, Kahan E. Ethnic variability in warfarin maintenance in the community setting: a population-based study in a managed care environment in Israel. Isr Med Assoc J 2007; 9: 12-5.
21. Wivanitkit V. Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations. Clin Appl Thromb Hemost 2006; 12: 219-22.
22. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
23. Williams RL, Schary WL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin. Clin Phamacol Ther 1976; 20: 90-7.
24. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
25. Malhi H, Atac B, Daly AK, Gupta S. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgrad Med J 2004; 80: 107-9.